Record H1 Revenue and EBITDA Drive Kamada's 2026 Guidance Affirmation; CFO Departure Announced
KMDA is trading near its 52-week low of $6.5 (11% above the low).
Summary
Record H1 2026 results featured double-digit revenue and profit growth, full-year guidance was reaffirmed, and the CFO's planned year-end departure was disclosed.
Key Events · Earnings and Guidance · KMDA
-
Record H1 Revenue and Profit
H1 2026 revenues reached $100.2 million, up 13% year-over-year, while adjusted EBITDA grew 14% to $25.7 million. The second quarter was particularly strong, with revenues surging 23% to $54.9 million and adjusted EBITDA jumping 29% to $14.1 million.
-
2026 Guidance Reaffirmed
Management reiterated its full-year 2026 outlook of $200–$205 million in revenues and $50–$53 million in adjusted EBITDA, implying growth of 12% and 23% at the midpoints, respectively.
-
CFO Transition Announced
CFO Chaime Orlev will step down effective December 31, 2026, to pursue other opportunities. A search for a successor is underway, and Orlev will provide transitional support.
-
Strong Cash Generation
Operating cash flow more than doubled to $17.8 million in H1 2026, compared with $7.5 million in H1 2025, reflecting improved conversion of profitability.
Analysis · KMDA · Life Sciences
The strongest half in the company's history saw revenues climb 13% to $100.2 million and adjusted EBITDA rise 14% to $25.7 million. With full-year guidance of $200–$205 million in revenue and $50–$53 million in adjusted EBITDA reaffirmed, double-digit organic growth remains on track. While the planned CFO transition introduces some uncertainty, a search is already underway and the outgoing CFO will remain through year-end to ensure a seamless handover.
At the time of this filing, KMDA was trading at $7.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $409.1M. The 52-week trading range was $6.50 to $9.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.